ILADS Lyme Disease Guidelines Rank in Top 5% of Research Articles
The ILADS Lyme disease guidelines have ranked in the top 5% of all research articles, based on Altmetric scoring—highlighting their reach and influence beyond traditional citation metrics. :contentReference[oaicite:0]{index=0}
What Is an Altmetric Score?
Altmetrics track how research is discussed and shared across news outlets, social media, policy documents, and other public platforms.
Unlike traditional citation counts, Altmetrics reflect how research is influencing real-world conversations, clinical thinking, and public awareness.
A high score suggests that a publication is gaining attention and shaping discussion within and beyond the medical community.
Why the ILADS Guidelines Were Developed
The ILADS guidelines were developed in response to:
- Persistent and chronic manifestations of Lyme disease
- Growing patient and clinician concern
- Ongoing debate over treatment approaches
They were created using the GRADE framework, which evaluates evidence based on:
- Balance of benefits and risks
- Quality of evidence
- Patient values and preferences
- Resource use
This structured approach aims to provide transparent, patient-centered recommendations.
Adoption in Clinical Practice
Evidence suggests that aspects of these guidelines are already being adopted in practice.
Survey data indicate that:
- 50% of physicians in New England believe prolonged antibiotic therapy is sometimes useful
- 25% believe it is always useful
Insurance claims data also reflect similar patterns:
- 18% of patients received extended antibiotic therapy
- Average treatment duration was approximately 86 days
- Nearly half of patients were treated with more than one antibiotic
These findings suggest that clinicians are already individualizing treatment in response to patient needs.
Beyond Guidelines: Real-World Impact
The widespread discussion and application of the ILADS guidelines reflect their relevance in clinical care.
At the same time, variation in treatment approaches highlights the complexity of Lyme disease management.
Clinical Perspective
The ILADS guidelines represent an effort to address the variability seen in Lyme disease outcomes using a structured, evidence-based framework.
Their high Altmetric ranking suggests that they are influencing both clinical practice and broader conversations about Lyme disease.
Whether wider implementation improves long-term outcomes remains an important question.
Patients may benefit from understanding treatment variability, reviewing persistent symptoms, and considering ethical considerations when evaluating treatment options.
Key Takeaway
The ILADS guidelines are widely discussed and increasingly influential—reflecting ongoing efforts to address the complexity of Lyme disease care.
References
- Cameron DJ et al. Expert Rev Anti Infect Ther. 2014.
- Wormser GP et al. Clin Infect Dis. 2006.
- Tseng YJ et al. Clin Infect Dis. 2015.
- Macauda MM et al. Vector Borne Zoonotic Dis. 2011.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
